Brain Scientific Inc. BRSF

Company Overview

Brain Scientific Inc. (OTC: BRSF) has operated as a medical technology and neurology-focused company involved in diagnostic and motion-control technologies. Public disclosures and historical filings indicate that the company focused primarily on electroencephalogram (EEG) technologies and precision motion systems used in healthcare and industrial applications. Its business activities were associated with neurological diagnostics, remote healthcare applications, and piezoelectric motion-control solutions. Historical revenue drivers appear to have included sales and commercialization efforts tied to EEG systems and precision motion products through affiliated operating entities.

The company’s operations evolved through acquisitions and restructuring initiatives intended to expand its healthcare technology portfolio. Public records identify Piezo Motion Corp. as a significant subsidiary and operational asset tied to motion-control technologies. Brain Scientific also promoted compact EEG hardware intended to improve accessibility and portability in neurological diagnostics. Available public information indicates the company sought positioning at the intersection of digital healthcare, diagnostics, and precision engineering, although current operational scale and financial activity are difficult to independently verify from recent public disclosures. Data inconclusive based on available public sources regarding the company’s present operating status and long-term commercial scale.

Business Operations

Brain Scientific historically organized operations around healthcare diagnostics and motion-control technology businesses. Its principal operating activities included EEG diagnostic equipment commercialization and the development of piezoelectric motion systems through Piezo Motion Corp. The company’s EEG-related offerings were designed to support neurological testing and remote or portable healthcare environments, while the motion-control segment targeted applications in medical devices, robotics, semiconductor systems, and industrial automation.

The company’s operations were primarily U.S.-based, though public materials referenced broader commercialization opportunities in international healthcare and industrial markets. Brain Scientific controlled intellectual property and engineering capabilities associated with piezoelectric motor technology through Piezo Motion Corp. Historical company communications also referenced relationships with healthcare providers, diagnostic distributors, and industrial technology customers. Publicly verifiable information regarding major joint ventures or large-scale international partnerships remains limited. Data inconclusive based on available public sources regarding the current status of certain subsidiaries and commercial agreements.

Strategic Position & Investments

Brain Scientific’s strategic direction historically centered on expanding neurological diagnostic accessibility and advancing precision motion technologies for healthcare and industrial use. The company promoted growth initiatives tied to portable EEG systems, telehealth-compatible diagnostics, and compact motion-control technologies. Strategic emphasis was placed on miniaturization, energy efficiency, and applications requiring precise positioning systems.

A major strategic asset associated with the company was Piezo Motion Corp., which developed piezoelectric motors and motion-control systems for medical, semiconductor, aerospace, and robotics applications. Public filings and investor materials also referenced commercialization efforts surrounding FDA-cleared EEG products and intellectual property development. While historical disclosures discussed acquisition activity and technology expansion, independently verified information about recent investments, active acquisitions, or ongoing capital deployment is limited. Data inconclusive based on available public sources concerning the company’s most recent strategic initiatives and operational execution.

Geographic Footprint

Brain Scientific was headquartered in the United States, with historical operations and corporate activity concentrated primarily in the U.S. market. Its healthcare diagnostic initiatives targeted hospitals, clinics, and neurological specialists, while the motion-control business pursued industrial and medical technology customers domestically and internationally.

Public company materials referenced market opportunities across North America, Europe, and parts of Asia, particularly for motion-control technologies applicable to semiconductor manufacturing, robotics, and medical systems. However, independently verified evidence of substantial international operating infrastructure or material overseas revenue concentration is limited. Data inconclusive based on available public sources regarding the scale of the company’s current global operational footprint.

Leadership & Governance

Brain Scientific’s leadership historically included executives with backgrounds in healthcare technology, finance, and engineering. Public filings and company disclosures identified management personnel involved in both corporate strategy and subsidiary operations, particularly in relation to Piezo Motion Corp. The company’s strategic messaging emphasized innovation in healthcare accessibility, engineering-driven product development, and commercialization of proprietary technologies.

Key executives identified in historical public disclosures include:

• Harrison Ross – Former Chairman and executive leadership figure
• Baruch “Boris” Goldstein – Former Chief Executive Officer
• Vadim Gurevich – Executive associated with engineering and motion-control operations
• Denis Bourdages – Executive leadership role associated with operational activities at Piezo Motion Corp.

Public governance information indicates the company operated as a publicly traded issuer subject to reporting obligations through filings including SEC filings and OTC market disclosures. However, leadership composition and board structure may have changed, and some information could not be fully verified through recent public filings. Data inconclusive based on available public sources regarding the company’s current executive structure and governance status.